Gemini Therapeutics, Inc. (NASDAQ:GMTX – Get Free Report)’s share price shot up 3.6% during trading on Friday . The company traded as high as $53.30 and last traded at $52.71. 396,554 shares changed hands during mid-day trading, an increase of 109% from the average session volume of 189,291 shares. The stock had previously closed at $50.86.
Gemini Therapeutics Stock Up 3.6%
The firm has a 50 day moving average price of $45.47 and a 200 day moving average price of $53.39. The stock has a market capitalization of $2.28 billion, a PE ratio of -52.71 and a beta of -0.12.
About Gemini Therapeutics
Gemini Therapeutics, Inc, a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients.
Featured Stories
- Five stocks we like better than Gemini Therapeutics
- Energy and Oil Stocks Explained
- IBM Up 10 Days in a Row: What’s Driving the Winning Streak?
- Differences Between Momentum Investing and Long Term Investing
- Upstart Stock’s Bull Case Just Got a Lot Stronger
- High Flyers: 3 Natural Gas Stocks for March 2022
- Higher Gulf Oil Output Puts These Energy Names in Play
Receive News & Ratings for Gemini Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gemini Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
